Dexmedetomidine in the Treatment of Agitation Associated With Dementia
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation
associated with dementia when they occur (given as needed [PRN]), for a maximum of 28 doses
within a 12-week treatment period.